The global cancer immunotherapy drug discovery outsourcingmarket is project worth $1.8 Billion in 2026 and the market is projected to showcase 14.0% CAGR during the forecast period.
The market is driven by increasing cancer patients and surging awareness about developments and improvement in cancer immunotherapy.
Report coverage
Market | Cancer Immunotherapy Drug Discovery Outsourcing Market |
Analysis Period | 2015 - 2026 |
Base Year | 2017 |
Forecast Data | 2018 - 2026 |
Segments Covered | By Drug Type, By Service Type, By Cancer Type and By Geography |
Regional Scope | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Key Companies Profiled | Aquila BioMedical,Crown Bioscience, Inc.,Molecular Imaging, Inc.,Explicyte,Horizon Discovery Group PLC,STC Biologics,Promega Corporation,Personalis, Inc.,HD Biosciences Co.,DiscoverX Corporation,Genscript Biotech Corporation,BPS Bioscience, Inc.,ImmunXperts SA, andCelentyx Ltd. |
Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Customization Scope | 10 hrs of free customization and expert consultation |
Market Dynamics
Increase in occurrence of cancer disease and increasing mortality associated with cancer are the key reasons for the growth of the cancer immunotherapy drug discovery outsourcing market. Furthermore, supportive government regulation for healthcare sector is optimistically impacting the development of the market and is anticipated to drive the development during the forecast period.
Increasing number of cancer patients across the world drive the demand for better cancer treatment and diagnostics services globally during the forecast period. Also, Pharmaceutical businesses are concentrating on immunotherapies subsequently they are a potential treatment alternative for cancer due to their capability to shrink the risk of post chemotherapy tumor reoccurrence.
Furthermore, favourable tax credit permits pharmaceutical businesses to properly plan their global projects with a reputed CRO, which will help in them in growing their business and avoiding taxation related problems. This factor also contribute in the growth of the market.
Market Insights
The global cancer immunotherapy drug discovery outsourcingmarket is anticipated to account the substantial growth in the coming years, attributed to increasing alertness and awareness about developments in cancer immunotherapy paired with growing investments by pharmaceutical businesses in outsourcing and subcontracting is anticipated to boost in the growth of thecancer immunotherapy drug discovery outsourcing market.
Market Classification
The global cancer immunotherapy drug discovery outsourcing market is segmented into four major segment named drug type, service type, cancer type, and region. On the basis of drug type the cancer immunotherapy drug discovery outsourcing market is segmented intomonoclonal antibodies, immunomodulators, oncolytic viral therapies and cancer vaccines, and others. On the basis of the service type the global cancer immunotherapy drug discovery outsourcing market is segmented into target identification and validation, lead screening and characterization and cell based assays.On the basis of cancer type, the cancer immunotherapy drug discovery outsourcing market is segmented into lung, breast, colorectal, melanoma, prostate, head and neck, ovarian and pancreatic. On the basis of region the global Cancer Immunotherapy Drug Discovery Outsourcing market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Regional Insights
In 2018, North America accounts largest revenue share and the region is anticipated to continue its dominance over the forecast period as the region has domicile of big pharmaceutical giants. Other reason for the growth of the North America cancer immunotherapy drug discovery outsourcing market are high per capita healthcare expenditure, and increasing awareness about the canner treatment and diagnostic system.
Europe is anticipated to be the second fastest-developing market for cancer immunotherapy drug discovery outsourcing. Increased incidence of cancer diseases and occurrence of a huge target population base are the crucial factors growing demand for cancer immunotherapy drug discovery outsourcingin the region.
Market Participants
The major players associated with the cancer immunotherapy drug discovery outsourcing market Aquila BioMedical,Crown Bioscience, Inc.,Molecular Imaging, Inc.,Explicyte,Horizon Discovery Group PLC,STC Biologics,Promega Corporation,Personalis, Inc.,HD Biosciences Co.,DiscoverX Corporation,Genscript Biotech Corporation,BPS Bioscience, Inc.,ImmunXperts SA, andCelentyx Ltd.
Market Segmentation
Market ByDrug type
Market ByCancer type
Market ByService type
Market By Geography